Breast cancer risk by breast density, menopause, and postmenopausal hormone therapy use. Read more about Breast cancer risk by breast density, menopause, and postmenopausal hormone therapy use.
Deletion of the PER3 gene on chromosome 1p36 in recurrent ER-positive breast cancer. Read more about Deletion of the PER3 gene on chromosome 1p36 in recurrent ER-positive breast cancer.
Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 early-stage breast cancer patients. Read more about Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 early-stage breast cancer patients.
Phase II study of the anti-cytotoxic T-lymphocyte-associated antigen 4 monoclonal antibody, tremelimumab, in patients with refractory metastatic colorectal cancer. Read more about Phase II study of the anti-cytotoxic T-lymphocyte-associated antigen 4 monoclonal antibody, tremelimumab, in patients with refractory metastatic colorectal cancer.
Hypofractionated stereotactic radiation therapy: an effective therapy for recurrent high-grade gliomas. Read more about Hypofractionated stereotactic radiation therapy: an effective therapy for recurrent high-grade gliomas.
Brain tumors: from childhood through adolescence into adulthood. Read more about Brain tumors: from childhood through adolescence into adulthood.
Active surveillance for early-stage prostate cancer: defining the triggers for intervention. Read more about Active surveillance for early-stage prostate cancer: defining the triggers for intervention.
Intensity-modulated chemoradiotherapy aiming to reduce dysphagia in patients with oropharyngeal cancer: clinical and functional results. Read more about Intensity-modulated chemoradiotherapy aiming to reduce dysphagia in patients with oropharyngeal cancer: clinical and functional results.
Urologist density and county-level urologic cancer mortality. Read more about Urologist density and county-level urologic cancer mortality.
Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. Read more about Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval.
